These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16429393)

  • 1. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
    Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
    J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.
    Kim KR; Choi J; Hwang JE; Baik YA; Shim JY; Kim YM; Robboy SJ
    Histopathology; 2010 Oct; 57(4):587-96. PubMed ID: 20955384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular carcinogenesis of ovarian carcinoma].
    Diebold J
    Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
    Cao SN; Chang KH; Luthra R; Liu J
    Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis.
    Stewart CJ; Walsh MD; Budgeon CA; Crook ML; Buchanan DB
    Pathology; 2013 Oct; 45(6):559-66. PubMed ID: 24018808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
    Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
    Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis.
    Stewart CJ; Leung Y; Walsh MD; Walters RJ; Young JP; Buchanan DD
    Hum Pathol; 2012 Aug; 43(8):1177-83. PubMed ID: 22305241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.
    Gamallo C; Palacios J; Moreno G; Calvo de Mora J; Suárez A; Armas A
    Am J Pathol; 1999 Aug; 155(2):527-36. PubMed ID: 10433945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
    Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.